These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8565031

  • 1. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
    Overgaard K, Lindsay R, Christiansen C.
    Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 4. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 5. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 11. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 12. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Jul; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A, Romano L, Ronsini S, Riccio S, Montemagno U.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
    Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R.
    Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
    [Abstract] [Full Text] [Related]

  • 20. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, Sturtridge WC, Sebaldt RJ, Steele M, Gordon M, Themeles E, Tugwell P, Roberts R, Gent M.
    Br J Rheumatol; 1997 Feb; 36(2):255-9. PubMed ID: 9133941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.